McKesson Corp. (MCK)

133.77
1.16 0.86
NYSE : Distribution Services
Prev Close 134.93
Open 135.75
Day Low/High 132.96 / 135.75
52 Wk Low/High 106.11 / 149.43
Volume 493.57K
Avg Volume 1.35M
Exchange NYSE
Shares Outstanding 189.96M
Market Cap 25.35B
EPS 0.20
P/E Ratio 785.12
Div & Yield 1.56 (1.17%)
Stocks Under $10 Portfolio: Tax-Loss Selling Weighs on Indices

Stocks Under $10 Portfolio: Tax-Loss Selling Weighs on Indices

We used this week's declines to add to our positions in Teligent, Builders FirstSource and Sonus Networks.

McKesson Shares Plunge on Drug Price Cuts

McKesson Shares Plunge on Drug Price Cuts

Shares of the drug distributor were falling sharply Friday.

Stressed Out: Valeant Shareholders Flee on McKesson Warning

Stressed Out: Valeant Shareholders Flee on McKesson Warning

The drugmaker's shares were hammered Friday on news that the industry is slashing prices.

Trending Tickers: HSY, RCL, MCK, VRX

Trending Tickers: HSY, RCL, MCK, VRX

Hershey shares got an early Halloween treat Friday after earnings topped analyst forecasts.

Jim Cramer Explains Why Health Care Stocks are Getting Slammed on Wall Street Today

Jim Cramer Explains Why Health Care Stocks are Getting Slammed on Wall Street Today

McKesson's disappointing earnings report ignited a selloff in health care stocks, and Jim Cramer says investors are questioning the sector's future.

Jim Cramer: Healthcare Stocks in Crosshairs

Jim Cramer: Healthcare Stocks in Crosshairs

The pricing structure of the healthcare and drug distribution industry has been wrecked and Wall Street is taking down those stocks as a result, says Jim Cramer.

McKesson downgraded at Deutsche

McKesson downgraded at Leerink

Bullish & Bearish Reversals for the Week

Bullish & Bearish Reversals for the Week

Energy and consumer defensive names dominate on the bearish side.

McKesson's Correction Is not Just a Third-Quarter Issue

McKesson's Correction Is not Just a Third-Quarter Issue

Keep your powder dry and see if MCK tries to makes a double bottom.

McKesson downgraded at Goldman

Ignore the Political Debate and Buy These 4 Cheap Pharma Stocks

Ignore the Political Debate and Buy These 4 Cheap Pharma Stocks

McKesson is down 10 percent year-to-date due to the heated political debate over drug pricing but the stock is too cheap to ignore.

Cramer: The Answer to This Market: Part 1

Cramer: The Answer to This Market: Part 1

The leadership is quite stark.

'Timeliness' Isn't Always on Your Side

'Timeliness' Isn't Always on Your Side

In the case of McKesson, Value Line system doesn't do investors any favors.

Cramer: There Isn't Very Much to Buy, Despite the Dip

There are issues everywhere, in almost every group.

When Covered Call Writing Makes Sense

When Covered Call Writing Makes Sense

The strategy doesn't deserve a lot of the criticism it gets.

Not Messin' With McKesson (Long)

Charts push for the short position.

It Looks Like McKesson Is Forming a Bottom

But try to have your buy orders below the market, in the $165 area.

9 Health Names to Like Amid the Rhetoric

9 Health Names to Like Amid the Rhetoric

Candidates have decried rising drug and medical prices, but there are reasons to like these stocks.

McCormick Turns Up the Heat on Premier Foods

Undeterred by previous snubs, spicemaker McCormick makes a revised approach to Britain's Premier Foods, raising the proposed enterprise value to $2.16 billion.

Bearish Signals Are Rising

Bearish Signals Are Rising

The market went too far, too fast. 

Jim Cramer Says Procter & Gamble, Kimberly Clark Are 'Screaming Buys’

Jim Cramer Says Procter & Gamble, Kimberly Clark Are 'Screaming Buys’

TheStreet’s Jim Cramer says he thinks Visa will go up substantially, and that consumer products companies Kimberly Clark and Procter & Gamble are ‘screaming buys.'

U.S. Futures Take Negative Turn Following Conclusion of Fed Meeting

U.S. futures are falling premarket.

McKesson to Pay $1.2 Billion for Pair of Oncology Businesses

McKesson to Pay $1.2 Billion for Pair of Oncology Businesses

McKesson revealed Thursday a pair of acquisitions that will grow its oncology business.

McKesson Multiple Sits at Swell Entry Point

McKesson Multiple Sits at Swell Entry Point

Why be afraid to own a world leader in health care at a multiyear best valuation?

McKesson Could Use a Shot in the Arm; Chart Shows Potential 25% Downside

After reading the chart action, we see $120 as the next stopping point.

This Is What an Oversold Bounce Looks Like

But wait to see what the analysts do.

Futures Steady; What Does Cramer Pick for This Earnings Week?

Three Action Alerts PLUS holding are set to report results.

Plenty of Good News -- If You Look

Not all growth is hated today.